Preliminary report of extracorporeal blood purification therapy in patients receiving LVAD: Cytosorb or Jafron HA330

CONCLUSION: Our preliminary results showed that hemoadsorption therapy using Cytosorb or Jafron hemoadsorption (HA) 330 may not be clinically beneficial for patients with advanced heart failure undergoing LVAD implantation. Large prospective studies are needed to evaluate the potential role of HA therapy in improving outcomes in patients undergoing LVAD implantation.PMID:38488713 | PMC:PMC10941830 | DOI:10.1051/ject/2023048
Source: Journal of Extra-Corporeal Technology - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research